Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation by Joseph et al titled “Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database,” published online March 11, 2019, and also in the June print issue of JAMA Neurology,1 there was an error in the Results section of the Abstract. The fifth sentence should read, “After adjusting for age at last visit, mean hydrocortisone equivalent dose, mobility status, and bisphosphonate use prior to first fracture, boys treated with daily deflazacort had a 16.0-fold increased risk for first fracture (95% CI, 1.4-180.8; P = .03).” This article was corrected online. This article was also corrected in April 2019 to fix a group author that was incorrectly categorized.2
Error in Abstract. JAMA Neurol. 2019;76(6):732. doi:10.1001/jamaneurol.2019.1455
Create a personal account or sign in to: